<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906448</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201800600</org_study_id>
    <secondary_id>OCR17711</secondary_id>
    <nct_id>NCT03906448</nct_id>
  </id_info>
  <brief_title>FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) With Adjuvant Temozolomide in High Risk WHO Grade II and III Astrocytomas (FORWARD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with&#xD;
      newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with&#xD;
      adjuvant temozolomide versus temozolomide alone in historical controls after the completion&#xD;
      of definitive chemoradiotherapy. Study treatment may continue past first tumor recurrence.&#xD;
      The primary endpoint will be overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed high-risk Grade II or III astrocytoma must undergo maximal safe&#xD;
      resection (biopsy alone may be eligible) and chemoradiotherapy: concomitant 75mg/m2 daily&#xD;
      temozolomide with 80% prescribed dose completed and RT with minimal RT dose of 40 Gy&#xD;
      delivered.&#xD;
&#xD;
      Within three weeks prior to beginning adjuvant temozolomide, all patients will undergo a&#xD;
      Baseline contrast-enhanced MRI of the brain. Within two weeks prior to beginning adjuvant&#xD;
      temozolomide, all patients will undergo baseline assessments. Patients will begin study&#xD;
      treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no&#xD;
      later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the&#xD;
      latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will&#xD;
      be given. Patients will be seen and examined before each cycle of temozolomide. After a&#xD;
      maximum of 12 cycles of adjuvant temozolomide, patients will be seen every 8 weeks. Brain MRI&#xD;
      and QoL assessments will be performed every 8 weeks following the baseline MRI for the first&#xD;
      2 years then every 3 months thereafter until second progression (when TTFields treatment will&#xD;
      be terminated).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated because the Study Chair/IDE Sponsor and Novocure determined that&#xD;
    conducting this trial was not feasible without CMS approval.&#xD;
  </why_stopped>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Frequency of overall survival in study participants. 2 years of active treatment, lifelong survival follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Astrocytoma, Grade II</condition>
  <condition>Astrocytoma, Grade III</condition>
  <arm_group>
    <arm_group_label>Astrocytoma Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients newly diagnosed with Grade II and III astrocytoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Data collection from medical record only</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTFields with adjuvant temozolomide</intervention_name>
    <description>Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.</description>
    <arm_group_label>Astrocytoma Patients</arm_group_label>
    <other_name>Optune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Histologic confirmation of WHO Grade II or III astrocytoma---mixed oligoastrocytomas&#xD;
             are permitted&#xD;
&#xD;
          -  1p/19q intact per FISH and/or ATRX mutation(s) per immunohistochemistry or&#xD;
             next-generation sequencing (e.g. Foundation Medicine, TEMPUS, Caris, or similar&#xD;
             CLIA-certified sequencing service)&#xD;
&#xD;
          -  Mutational identity determined by CLIA-certified sequencing including:&#xD;
&#xD;
               1. IDH1/2 wildtype (i.e. lack of detectable mutations on the sequencing report) and&#xD;
&#xD;
               2. TERT promoter mutation&#xD;
&#xD;
          -  Karnofsky performance status ≥70%&#xD;
&#xD;
          -  Maximal safe resection---biopsy alone is allowed&#xD;
&#xD;
          -  Completed standard chemoradiation with total RT dose of at least 40 Gy and concurrent&#xD;
             temozolomide (75mg/m2 daily dose with 80% prescribed dose completed)&#xD;
&#xD;
          -  Patients with a tumor that was biopsied or resected in the past followed by&#xD;
             observation only without definitive chemoradiation and/or chemotherapy given will be&#xD;
             eligible, as long as: repeat maximal surgical resection (biopsy only allowed) has been&#xD;
             performed, definitive temozolomide/RT treatment meets the criteria above, and adjuvant&#xD;
             temozolomide treatment is planned&#xD;
&#xD;
          -  Candidate for adjuvant high dose temozolomide per investigator's clinical judgement&#xD;
&#xD;
          -  Adjuvant Temozolomide start date at least 4 weeks, but not more than 6 weeks, from the&#xD;
             later of last dose of concomitant temozolomide or radiotherapy&#xD;
&#xD;
          -  No evidence of early disease progression per RANO criteria at the time of enrollment&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using a highly effective method of&#xD;
             contraception to avoid pregnancy throughout the study and for at least 24 weeks after&#xD;
             the last dose of study drug to minimize the risk of pregnancy.&#xD;
&#xD;
               1. Prior to study enrollment, women of childbearing potential must be advised of the&#xD;
                  importance of avoiding pregnancy during trial participation and the potential&#xD;
                  risk factors for an unintentional pregnancy.&#xD;
&#xD;
               2. Refer to section 10.2.1 for guidance on highly effective contraceptive methods&#xD;
                  acceptable in this study.&#xD;
&#xD;
               3. WOCBP include any woman who has experienced menarche and who has not undergone&#xD;
                  successful surgical sterilization (hysterectomy, bilateral tubal ligation, or&#xD;
                  bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined&#xD;
                  as: Amenorrhea that has lasted for ≥ 12 consecutive months without another cause,&#xD;
                  or For women with irregular menstrual periods who are taking hormone replacement&#xD;
                  therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of&#xD;
                  greater than 35 mIU/mL.&#xD;
&#xD;
          -  Males with female partners of child-bearing potential must agree to use&#xD;
             physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy)&#xD;
             throughout the study and should avoid conceiving children for 24 weeks following the&#xD;
             last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with anti-angiogenic agents including bevacizumab.&#xD;
&#xD;
          -  Prior treatment with TTFields.&#xD;
&#xD;
          -  Progressive disease (according to RANO criteria) after temozolomide/RT.&#xD;
&#xD;
          -  Actively participating in another clinical treatment trial intended to treat the&#xD;
             underlying astrocytoma.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Significant co-morbidities at baseline (within 2 weeks prior to adjuvant temozolomide&#xD;
             start) which would prevent adjuvant temozolomide treatment:&#xD;
&#xD;
               1. Thrombocytopenia (platelet count &lt; 100 x 103/μL)&#xD;
&#xD;
               2. Neutropenia (absolute neutrophil count &lt; 1.5 x 103/μL)&#xD;
&#xD;
               3. CTC grade 4 non-hematological toxicity (except for alopecia, nausea, vomiting)&#xD;
&#xD;
               4. Significant liver function impairment - AST or ALT &gt; 5 times the upper limit of&#xD;
                  normal&#xD;
&#xD;
               5. Total bilirubin &gt; 2 times upper limit of normal&#xD;
&#xD;
               6. Significant renal impairment (GFR ≤ 30 ml/min)&#xD;
&#xD;
          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other&#xD;
             implanted electronic devices in the brain, or documented clinically significant&#xD;
             arrhythmias.&#xD;
&#xD;
          -  A skull defect such as missing bone with no replacement&#xD;
&#xD;
          -  Bullet fragments embedded the skull&#xD;
&#xD;
          -  Tumors located in the brain stem and/or the cerebellum&#xD;
&#xD;
          -  History of hypersensitivity reaction to temozolomide, Dacarbazine (DTIC) or hydrogel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tran, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Health at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health Morsani College of Medicine-Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University-Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <results_first_submitted>August 26, 2021</results_first_submitted>
  <results_first_submitted_qc>August 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03906448/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03906448/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Astrocytoma Patients</title>
          <description>Patients newly diagnosed with Grade II and III astrocytoma.&#xD;
TTFields with adjuvant temozolomide: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Data collection from medical record only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No subjects were enrolled in the control arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Astrocytoma Patients</title>
          <description>Patients newly diagnosed with Grade II and III astrocytoma.&#xD;
TTFields with adjuvant temozolomide: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Data collection from medical record only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Frequency of overall survival in study participants. 2 years of active treatment, lifelong survival follow-up.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Astrocytoma Patients</title>
            <description>Patients newly diagnosed with Grade II and III astrocytoma.&#xD;
TTFields with adjuvant temozolomide: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Data collection from medical record only</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Frequency of overall survival in study participants. 2 years of active treatment, lifelong survival follow-up.</description>
          <population>This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>after the start of study treatment for 30 days after the After Treatment Stop Visit</time_frame>
      <desc>The control arm was a historical control.</desc>
      <group_list>
        <group group_id="E1">
          <title>Astrocytoma Patients</title>
          <description>Patients newly diagnosed with Grade II and III astrocytoma.&#xD;
TTFields with adjuvant temozolomide: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Data collection from medical record only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <description>Inpatient Hospitalization for repeat brain tumor resection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Disease progression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>metastatic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Reactive Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Tran, MD, PhD</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-9000</phone>
      <email>david.tran@neurosurgery.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

